Multidisciplinary Journal of Science and Technology

SAFETY AND EFFICACY OF LONG-TERM TREATMENT WITH NUCLEOS(T)IDE ANALOGUES IN CHRONIC HEPATITIS B

Bakhtiyarova Dilnura Akbarovna

Keywords: chronic hepatitis B, nucleos(t)ide analogues, antiviral therapy, safety, efficacy, HBV DNA

Abstract

Chronic hepatitis B (CHB) remains a major global public health problem, leading to progressive liver disease, cirrhosis, and hepatocellular carcinoma. Long-term antiviral therapy with nucleos(t)ide analogues (NAs) is the cornerstone of CHB management, aiming to suppress hepatitis B virus (HBV) replication, prevent disease progression, and reduce liver-related complications. Despite proven antiviral efficacy, prolonged NA therapy raises concerns regarding drug resistance, safety, renal and bone toxicity, and long-term patient adherence.

This study was conducted at the Khorezm Regional Multidisciplinary Medical Center and aimed to evaluate the safety and efficacy of long-term treatment with nucleos(t)ide analogues in patients with chronic hepatitis B. Patients were assessed based on virological, biochemical, and clinical parameters during extended antiviral therapy. The results demonstrate that long-term NA treatment effectively suppresses HBV replication, improves liver function, and is generally well tolerated, confirming the importance of continuous antiviral therapy in the management of chronic hepatitis B.

References

1. Anagul, S., & Shakhlo, Y. (2026). Modern approaches to early detection and therapy of hepatorenal syndrome. Frontiers of Knowledge and Interdisciplinary Discovery, 2(1), 326–335.

2. Buti M., Tsai N., Petersen J., et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60(5):1457–1464.

3. Marcellin P., Gane E., Buti M., et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B. Hepatology. 2013;58(2):593–600.

4. Terrault N.A., Lok A.S.F., McMahon B.J., et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B. Hepatology. 2018;67(4):1560–1599.

5. Papatheodoridis G.V., Chan H.L., Hansen B.E., Janssen H.L., Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with antiviral therapy. J Hepatol. 2015;62(4):956–967.

6. Yusupova, S. B., & Ikramov, M. D. (2026). Development of chronic kidney disease in non-alcoholic fatty liver disease. Frontiers of Knowledge and Interdisciplinary Discovery, 2(1), 382–389.

7. Yusupova, S. B., & Palvonova, G. U. (2026). Non-alcoholic fatty liver disease and chronic kidney disease: Physiological changes. Frontiers of Knowledge and Interdisciplinary Discovery, 2(1), 390–399.